Remark: Newer agents (eg, ticagrelor) can be considered where bleeding risk is low. Data on the combination of ticagrelor with either dabigatran 110 mg bid or 150 bid (without concomitant aspirin use) are available from the RE-DUAL PCI trial. *31. For patients with AF and stable coronary artery disease (eg, no acute coronary syndrome within the previous year) and who choose oral anticoagulation, we suggest OAC with either an NOAC or adjusted- dose VKA therapy alone (target international normalized ratio [INR] range, 2.0-3.0) rather than the combination of OAC and aspirin (Weak recommendation, low quality evidence). 